INCYTE CORP (INCY)
Services-Commercial Physical & Biological Research · Services-Commercial Physical & Biological Research · NASDAQ
$128.47
+4.05%
Investingg Score
71.6 / 100
Buy
Business overview
- Gross margin of 92.8%
- Operating margin of 29.5%
These high margins demonstrate efficient core operations and strong pricing power in commercial physical and biological research services.
Financial health
- Free cash flow margin data unavailable
- Free cash flow yield data unavailable
While operating profitability is solid, the lack of cash flow metrics limits a complete evaluation of financial health.
- Gross Margin
- 92.8%
- Operating Margin
- 29.5%
- Current Ratio
- 3.3x
- Debt / Equity
- Data unavailable
- Free Cash Flow (TTM)
- Data unavailable
- Interest Coverage
- 624x
Valuation
- P/E ratio of 19.75
- Forward P/E of 18.1
- P/S ratio of 5.2
- EV to EBITDA and free cash flow yield data unavailable
These moderate earnings multiples suggest the stock is reasonably priced relative to its current profits, though missing cash flow metrics create valuation uncertainty.
- P/E (TTM)
- 19.8x
- Forward P/E
- 18.1x
- Price / Sales
- 5.2x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Absence of free cash flow margin and yield data limits visibility into cash generation.
- EV to EBITDA ratio is unavailable, restricting alternative valuation analysis.
- High relative strength index of 62.52 suggests the stock is approaching short-term overbought levels.
Market cap $25.5B · data as of 2026-08-19
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze INCY with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.